Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Life Sciences Industry Analysis

UpdatedJun 22, 2026
DataAggregated Company Financials
Companies65
  • 7D-0.8%
  • 3M5.0%
  • 1Y9.1%
  • YTD-15.4%

Over the last 7 days, the Life Sciences industry has remained flat, although notably 10x Genomics gained 7.9%. The past year has been better, since the industry has gained 9.1% in that time. Earnings are forecast to grow by 17% annually.

Industry Valuation and Performance

Has the U.S. Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 22 Jun 2026US$576.2bUS$150.6bUS$13.7b40.5x42x3.8x
Wed, 20 May 2026US$527.9bUS$150.3bUS$14.0b32.2x37.7x3.5x
Fri, 17 Apr 2026US$594.5bUS$147.8bUS$14.1b38.1x42.2x4x
Sun, 15 Mar 2026US$536.1bUS$147.8bUS$14.0b34.3x38.3x3.6x
Tue, 10 Feb 2026US$618.0bUS$147.4bUS$12.9b36.4x48.1x4.2x
Thu, 08 Jan 2026US$701.7bUS$145.8bUS$12.4b37.1x56.8x4.8x
Sat, 06 Dec 2025US$666.1bUS$145.8bUS$12.5b35.7x53.4x4.6x
Mon, 03 Nov 2025US$648.1bUS$145.4bUS$12.2b36x53.3x4.5x
Wed, 01 Oct 2025US$552.4bUS$144.3bUS$14.6b30.2x38x3.8x
Fri, 29 Aug 2025US$578.9bUS$144.3bUS$14.6b29x39.8x4x
Sun, 27 Jul 2025US$585.5bUS$143.7bUS$8.8b40.1x66.5x4.1x
Tue, 24 Jun 2025US$521.0bUS$142.9bUS$9.2b35.3x56.8x3.6x
Thu, 22 May 2025US$522.0bUS$142.8bUS$9.1b32.1x57.4x3.7x
Sat, 19 Apr 2025US$504.0bUS$142.6bUS$10.0b34.3x50.6x3.5x
Mon, 17 Mar 2025US$597.5bUS$143.1bUS$9.8b38.6x61.2x4.2x
Wed, 12 Feb 2025US$643.4bUS$143.2bUS$11.1b37.2x57.7x4.5x
Fri, 10 Jan 2025US$677.6bUS$142.4bUS$10.2b43.7x66.4x4.8x
Sun, 08 Dec 2024US$664.3bUS$142.4bUS$10.2b44.2x65x4.7x
Tue, 05 Nov 2024US$689.5bUS$142.3bUS$9.0b39.1x76.8x4.8x
Thu, 03 Oct 2024US$752.7bUS$141.8bUS$8.5b39.3x88.6x5.3x
Sat, 31 Aug 2024US$746.6bUS$141.8bUS$8.5b37.8x87.9x5.3x
Mon, 29 Jul 2024US$732.9bUS$141.0bUS$12.6b37.3x58.3x5.2x
Wed, 26 Jun 2024US$696.3bUS$141.3bUS$12.2b38.2x57.2x4.9x
Fri, 24 May 2024US$735.1bUS$141.5bUS$12.4b38.7x59.2x5.2x
Sun, 21 Apr 2024US$681.6bUS$142.0bUS$12.8b40.8x53.3x4.8x
Tue, 19 Mar 2024US$742.5bUS$142.1bUS$12.8b44.3x57.8x5.2x
Thu, 15 Feb 2024US$697.5bUS$142.2bUS$12.8b43x54.3x4.9x
Sat, 13 Jan 2024US$684.9bUS$153.9bUS$14.2b35.4x48.3x4.5x
Mon, 11 Dec 2023US$644.8bUS$153.7bUS$14.0b35.2x46x4.2x
Wed, 08 Nov 2023US$590.2bUS$153.9bUS$11.0b30.9x53.6x3.8x
Fri, 06 Oct 2023US$642.5bUS$154.6bUS$11.2b33x57.4x4.2x
Sun, 03 Sep 2023US$735.8bUS$154.6bUS$11.2b33.1x65.7x4.8x
Tue, 01 Aug 2023US$727.5bUS$154.7bUS$11.6b31.1x62.6x4.7x
Thu, 29 Jun 2023US$680.9bUS$152.4bUS$12.5b29.5x54.4x4.5x
Price to Earnings Ratio

54.4x


Total Market Cap: US$680.9bTotal Earnings: US$12.5bTotal Revenue: US$152.4bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Life Sciences Industry Price to Earnings3Y Average 56.2x202420252026
Current Industry PE
  • Investors are pessimistic on the American Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 42.0x which is lower than its 3-year average PE of 56.2x.
  • The 3-year average PS ratio of 4.4x is higher than the industry's current PS ratio of 3.8x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have grown 3.1% per year over the last three years, while revenues have remained mostly flat.
  • This means that companies overall are more efficiently conducting business since profits are increasing while sales have been flat.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market1.40%
Healthcare-1.82%
Life Sciences-0.82%
Clinical Research and Equipment-0.82%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
TXG 10x GenomicsUS$34.767.9%
+US$321.8m		222.1%PS6.9x
TECH Bio-TechneUS$57.943.2%
+US$277.1m		17.5%PE82.8x
STVN Stevanato GroupUS$17.545.5%
+US$248.4m		-25.2%PE29.6x
BRKR BrukerUS$57.231.1%
+US$91.3m		47.8%PS2.5x
ALMR Alamar BiosciencesUS$21.966.1%
+US$88.0m		n/aPS17.5x

Latest News

A
US$127.06
Agilent Technologies
7D
-2.7%
1Y
9.4%
ABCL
US$5.53
AbCellera Biologics
7D
5.1%
1Y
66.1%
TEM
US$50.84
Tempus AI
7D
-2.8%
1Y
-22.6%
Analysis Article • Jun 19

Tempus AI (TEM) Stock Could Be 22.9% Undervalued After ECG AF Validation

Tempus AI (TEM) is back in focus after publishing a multi site validation of its FDA cleared ECG AF software, which predicts one year atrial fibrillation or flutter risk in older adults without prior AF. See our latest analysis for Tempus AI. Tempus AI’s shares have picked up momentum recently, with a 1 month share price return of 10.81% and a 7 day gain of 6.32%. However, the year to date share price return is still down 18.47% and the 1 year total shareholder return has declined 25.57%...
DHR
US$177.17
Danaher
7D
-2.2%
1Y
-9.8%
VRXA
US$4.48
Veraxa Biotech
7D
-78.9%
1Y
-56.8%
PSNL
US$10.54
Personalis
7D
7.7%
1Y
69.7%
Narrative Update • Jun 19

PSNL: Recent Coverage, Clinical Progress And Losses Will Shape Longer Term Upside

Analysts have reduced their price targets on Personalis stock by about $1 to $2, citing updated fair value estimates near $9.00, an adjusted discount rate, and refreshed assumptions for revenue growth, profit margins, and future P/E multiples. Analyst Commentary on Personalis Stock Recent research updates around Personalis reflect a more cautious tone, with price targets trimmed by about $1 to $2 as bearish analysts reassess valuation and execution risks.
TXG
US$34.76
10x Genomics
7D
7.9%
1Y
222.1%
TECH
US$57.94
Bio-Techne
7D
3.2%
1Y
17.5%
Narrative Update • Jun 17

TECH: Portfolio Rebrand And Exosome Exit Will Support Future Margin Upside

Analysts have trimmed their Bio-Techne price target slightly from $76.00 to $75.00, reflecting updated views on revenue growth, discount rate and profit margin assumptions, while keeping long term P/E expectations broadly similar. What’s in the News for Bio-Techne Bio-Techne reported 3% organic revenue growth in Q4 fiscal 2025 and maintained profitability in what management described as challenging market conditions, according to its Q4 2025 earnings transcript.
TMO
US$464.61
Thermo Fisher Scientific
7D
-1.9%
1Y
16.1%
Analysis Article • Jun 17

Thermo Fisher Scientific (TMO) Stock Could Be 23% Below Fair Value After Neutral Rating

Piper Sandler’s new Neutral rating on Thermo Fisher Scientific (TMO), alongside a Material Transfer Agreement with Polymer Factory Sweden AB, has drawn fresh attention to how the stock reflects industry conditions and emerging technology partnerships. See our latest analysis for Thermo Fisher Scientific. Thermo Fisher Scientific’s latest share price of $472.63 sits against a mixed backdrop, with the stock down 20.23% on a year to date share price basis but delivering a 21.55% total...
STVN
US$17.54
Stevanato Group
7D
5.5%
1Y
-25.2%
Narrative Update • Jun 15

STVN: GLP-1 Exposure And Biologics Focus Will Support Future Earnings Power

Analysts have trimmed their price target on Stevanato Group to about $24.39 from $24.81, citing updated assumptions for the discount rate, revenue growth, profit margins, and future P/E. Recent Street research has also highlighted the company’s exposure to biologics and GLP-1 related demand.
BRKR
US$57.23
Bruker
7D
1.1%
1Y
47.8%
WST
US$327.95
West Pharmaceutical Services
7D
-1.1%
1Y
51.3%
ILMN
US$161.93
Illumina
7D
-3.0%
1Y
78.7%
Narrative Update • Jun 15

ILMN: Future Returns Will Hinge On Clinical Sequencing Momentum And Customer Stickiness

Narrative Update: Illumina The analyst price target underpinning this Illumina narrative has been raised from about $136 to $147, reflecting updated assumptions around customer stickiness, clinical sequencing momentum, and expectations for higher instrument and consumables spending highlighted in recent research. Analyst Commentary Recent research on Illumina reflects a mix of enthusiasm about the company’s position in sequencing markets and some ongoing caution around execution and valuation, with several major firms updating ratings and price targets.
IQV
US$167.77
IQVIA Holdings
7D
-6.0%
1Y
8.1%
Narrative Update • Jun 14

IQV: AI Initiatives And B2B Demand Will Support Earnings Reacceleration

IQVIA Holdings' implied fair value has been trimmed by about $1.65 to roughly $226.95, reflecting analysts' lower price targets around $210 in response to cautious sentiment on life science tools, even as they see early signs of recovery in areas like bioprocessing and quality assurance. Analyst Commentary Recent research points to a mixed setup for IQVIA Holdings, where cautious sentiment on life science tools is bumping up against early signs of recovery in specific end markets.
RGEN
US$132.02
Repligen
7D
0.9%
1Y
9.9%
Narrative Update • Jun 13

RGEN: Bioprocess Recovery And Training Hub Expansion Will Guide Future Performance

Repligen's analyst price target has been reset slightly lower to $142, as analysts factor in a modestly higher discount rate along with still-supportive views on bioprocessing demand and the broader life science tools recovery. Analyst Commentary Recent Street research around Repligen reflects a mixed setup, with several firms trimming price targets and a few others highlighting potential recovery in bioprocessing demand.
ALMR
US$21.96
Alamar Biosciences
7D
6.1%
1Y
n/a